Dementia / − nikotyna

Method for the prevention of dementia and Alzheimer's disease

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION The present invention is directed to a mode of treatment of a client to prevent dementia and Alzheimer's disease. For purposes of the present invention, dementia is defined to include Alzheimer's disease. Unmodified dementia risk is the population of the world. Millions

Methods for treating vascular dementia

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

Methods for treating dementia due to HIV disease

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

Methods for treating cognitive impairments or dementia

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or

Nicotine derivatives that enhance cognitive function

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

TECHNICAL FIELD This invention relates to nicotine derivatives and pharmaceutical compositions thereof which are cholinergic agonists selective for neuronal nicotinic receptors, to methods for preparing these compounds, to synthetic intermediates employed in these processes and to a method of

Aminoadamantane derivatives as therapeutic agents

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

(N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION This invention relates to heterocyclic compounds. More particularly it relates to (N-(pyridinylmethyl)-heterocyclic)-2-ylideneamine compounds of the formula I below. Compounds of formula I are useful in the treatment of addictive disorders such as the use of tobacco or

Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to pharmaceutical compositions, particularly pharmaceutical compositions that are capable of affecting nicotinic acetylcholine receptors (nAChRs). More importantly, the present invention relates to compounds capable of activating nAChRs, for

Method of treating memory impairment

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

The present invention is directed to devices and methods for treating memory impairment. More particularly, the present invention is directed to providing devices for the controlled release of compounds effective in treating memory impairment, and to methods for treating memory impairment comprising

1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to a group of 1-substituted-2-azabicyclo-[3.1.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing 1-substituted-2-azabicyclo-[3.1.1]heptyl derivatives belonging to this group. The

Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing substituted-7-azabicyclo-[2.2.1]heptyl derivatives belonging to this group. The

Phenyl-substituted nicotinic ligands, and methods of use thereof

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

Phenyl-substituted nicotinic ligands, and methods of use thereof

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

dementia/− nikotyna

Method for the prevention of dementia and Alzheimer's disease

Methods for treating vascular dementia

Methods for treating dementia due to HIV disease

Methods for treating cognitive impairments or dementia

Nicotine derivatives that enhance cognitive function

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

(N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents

Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands

Method of treating memory impairment

1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders

Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions

Phenyl-substituted nicotinic ligands, and methods of use thereof

Phenyl-substituted nicotinic ligands, and methods of use thereof

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo